Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

NCT04599933
View directory record Official record
Conditions
Presbyopia
Interventions
CSF-1, Vehicle
Drug
Lead sponsor
Orasis Pharmaceuticals Ltd.
Industry
Eligibility
45 Years to 64 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Sun City, Arizona • Glendale, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

NCT06249152
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions
QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Art Therapy in Progressive Supranuclear Palsy

NCT07820878
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP), Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS), Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R), Progressive Supranuclear Palsy
Interventions
Art Thrapy
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of Dream OCT: AP Study

NCT07355491
View directory record Official record
Conditions
Glaucoma Patients, Retina Patients, Eyes With Corneal Abnormality, Normal Healthy Eyes
Interventions
This is an observational study only, all patients are imaged on the investigational device
Device
Lead sponsor
Intalight, Inc
Industry
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 23, 2026, 10:21 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360
View directory record Official record
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 23, 2026, 10:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness of a Procedure for Previously Failed Glaucoma Surgery

NCT00347789
View directory record Official record
Conditions
Glaucoma
Interventions
Glaucoma surgery- Bleb revision
Procedure
Lead sponsor
Glaucoma Research & Education Group
Other
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Active Approach to Treat Amblyopia: Perceptual Learning and Video Games

NCT01115283
View directory record Official record
Conditions
Amblyopia
Interventions
Perceptual learning, Video Games, Occlusion therapy
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
5 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 23, 2026, 10:21 AM EDT
Completed No phase listed Observational

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

NCT00001161
View directory record Official record
Conditions
Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 10:21 AM EDT
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
View directory record Official record
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 23, 2026, 10:21 AM EDT
Enrolling by invitation Phase 2 Interventional

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

NCT07264283
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy
Interventions
LM11A-31, Matching Placebo
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Not listed Phase 4 Interventional

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

NCT04863742
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

NCT03489941
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
EM-100, Zaditor®, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05728944
View directory record Official record
Conditions
Presbyopia, Near Vision, Refractive Error, Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Dothan, Alabama • Scottsdale, Arizona • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pupillometry and Locus Coeruleus Activation (PuLCA)

NCT04579653
View directory record Official record
Conditions
Visual Impairment, Ocular Illness
Interventions
transcutaneous electrical nerve stimulation devices
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Treating Psychosocial Distress in Glaucoma

NCT06053307
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Distress, Emotional, Anxiety, Depression
Interventions
Acceptance commitment therapy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Theanine and Caffeine on Neurophysiology of Attention

NCT02770105
View directory record Official record
Conditions
L-theanine
Interventions
Theanine, Caffeine, Theanine-Caffeine Combination, Placebo
Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

NCT00347594
View directory record Official record
Conditions
Healthy
Interventions
Next Generation Diagnostic Instrument (NGDI), Zyoptix Diagnostic Workstation (ZDW)
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
21 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adaptive Optics Retinal Imaging

NCT05370287
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
oxygen inhalation, Adaptive optics imaging
Other · Device
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 23, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 23, 2026, 10:21 AM EDT